Thymosin Alpha-1 half-life & pharmacokinetics

Reported half-life

Approximately 2 hours plasma half-life after subcutaneous administration. Functional immunomodulatory effects persist substantially longer through downstream effects on T-cell function and dendritic-cell maturation. Standard clinical regimens in registered jurisdictions use twice-weekly subcutaneous dosing for chronic hepatitis and other chronic immune-modulation indications.

The half-life and pharmacokinetic profile of Thymosin Alpha-1 reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Subcutaneous injection (standard clinical route in registered jurisdictions)
• Intramuscular injection (research)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Synthetic acetylated 28-amino-acid peptide identical to the endogenous thymic peptide thymosin alpha-1; T-cell maturation and Toll-like receptor pathway immune modulator.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Thymosin Alpha-1 acts as follows:

Thymosin alpha-1 (Tα1) is a 28-amino-acid N-terminally acetylated peptide (sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN) originally isolated from bovine thymic Fraction 5 by Allan Goldstein's laboratory at the George Washington University in 1977, subsequently identified as an endogenous peptide produced by thymic epithelial cells through post-translational processing of the larger 113-amino-acid prothymosin alpha precursor. The synthetic recombinant peptide is identical to the endogenous form; the pharmaceutical product is manufactured by solid-phase peptide synthesis rather than biological source, avoiding the porcine/bovine biological-source complications of some other historical thymic-peptide preparations.

See the full Thymosin Alpha-1 research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.